ArticleBiogerontology2026
Salidroside ameliorates skin aging in male mice by promoting collagen regeneration via modulation of FOS and MMP9.
Article in Biogerontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Salidroside, a phenolic compound derived from Rhodiola rosea L., has been widely utilized in cosmetics and medicine for its anti-melanogenic properties. However, its role in collagen regeneration during skin aging remains unclear. In this study, we investigated the effects of salidroside on collagen synthesis and explored its underlying mechanisms in a murine model of skin aging. Administering salidroside (20, 40, and 80 mg/kg) orally for 28 days significantly increased dermal thickness, collagen volume, and the expression of collagen I and III in male mouse skin. Bioinformatic analysis of RNA-seq data from the GSE278079 dataset revealed enhanced neutrophil infiltration in aged skin, suggesting a role for inflammatory processes in skin aging. Furthermore, salidroside up-regulated the expression of the transcription factor FOS and down-regulated matrix metalloproteinase MMP9, both in vivo and in L929 fibroblasts. These changes correlated with reduced collagen degradation and enhanced fibroblast activity. Crucially, siRNA-mediated silencing of Fos in vitro partially diminished the salidroside-induced upregulation of collagen expression, substantiating a causal regulatory role for FOS in this process. Our results demonstrate that salidroside promotes collagen regeneration and mitigates skin aging, which is closely associated with the attenuation of neutrophil-mediated inflammation, alongside the upregulation of FOS and downregulation of MMP9. These findings highlight the therapeutic potential of salidroside in combating age-related skin changes.
Indexed as
Identifiers
41961336What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.